Adam Halberstadt

TitleAssistant Adjunct Professor
InstitutionUniversity of California San Diego
Address9500 Gilman Drive #0804
La Jolla CA 92093
vCardDownload vCard

    Collapse Biography 
    Collapse Education and Training
    University of California San DiegoPost-doc2012Psychopharmacology
    University of PittsburghPh.D.2006Neurobiology
    University of DelawareB.A.1998Biology, Psychology
    Collapse Awards and Honors
    NIDA2009  - 2012F32 NRSA post-doctoral fellowship
    NIDCD2004  - 2006Individual F31 NRSA predoctoral fellowship
    NIMH2014  - 2016K01 Career Development Award
    International Society for Serotonin Research2013  - 2020Associate Councilor
    Serotonin Club2008Travel Award
    American College of Neuropsychopharmacology2011Travel Award
    American College of Neuropsychopharmacology2018Associate Member

    Collapse Overview 

    Collapse Research 
    Collapse Research Activities and Funding
    The Next Generation of Hallucinogens: A New Class of Synthetic Psychoactive Drugs
    NIH/NIDA R01DA041336Feb 15, 2017 - Dec 31, 2020
    Role: Principal Investigator
    Role of the prefrontal cortex in serotonergic modulation of interval timing
    NIH/NIMH K01MH100644Jan 9, 2014 - Dec 31, 2016
    Role: Principal Investigator
    Mechanisms of hallucinogen effects on exploratory behavior in rats and mice
    NIH/NIDA F32DA025412May 1, 2009 - Apr 30, 2012
    Role: Principal Investigator
    Raphe Nuclei Projections to Vestibular Nuclei
    NIH/NIDCD F31DC006772Jul 4, 2004 - Jul 3, 2006
    Role: Principal Investigator

    Collapse ORNG Applications 
    Collapse Featured Publications

    Collapse Bibliographic 
    Collapse Publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Researchers can login to make corrections and additions, or contact us for help.
    List All   |   Timeline
    1. Klein LM, Cozzi NV, Daley PF, Brandt SD, Halberstadt A. Receptor binding profiles and behavioral pharmacology of ring-substituted N,N-diallyltryptamine analogs. Neuropharmacology. 2018 Feb 27. PMID: 29499272.
      View in: PubMed
    2. Halberstadt A, Geyer MA. Effect of Hallucinogens on Unconditioned Behavior. Curr Top Behav Neurosci. 2018; 36:159-199. PMID: 28224459.
      View in: PubMed
    3. Brandt SD, Kavanagh PV, Twamley B, Westphal F, Elliott SP, Wallach J, Stratford A, Klein LM, McCorvy JD, Nichols DE, Halberstadt A. Return of the lysergamides. Part IV: Analytical and pharmacological characterization of lysergic acid morpholide (LSM-775). Drug Test Anal. 2018 Feb; 10(2):310-322. PMID: 28585392.
      View in: PubMed
    4. Brandt SD, Kavanagh PV, Westphal F, Elliott SP, Wallach J, Stratford A, Nichols DE, Halberstadt A. Return of the lysergamides. Part III: Analytical characterization of N6 -ethyl-6-norlysergic acid diethylamide (ETH-LAD) and 1-propionyl ETH-LAD (1P-ETH-LAD). Drug Test Anal. 2017 Oct; 9(10):1641-1649. PMID: 28342178.
      View in: PubMed
    5. Halberstadt A. Hallucinogenic Drugs: A New Study Answers Old Questions about LSD. Curr Biol. 2017 Feb 20; 27(4):R156-R158. PMID: 28222297.
      View in: PubMed
    6. Halberstadt A. Pharmacology and Toxicology of N-Benzylphenethylamine ("NBOMe") Hallucinogens. Curr Top Behav Neurosci. 2017; 32:283-311. PMID: 28097528.
      View in: PubMed
    7. Cope ZA, Halberstadt A, van Enkhuizen J, Flynn AD, Breier M, Swerdlow NR, Geyer MA, Young JW. Premature responses in the five-choice serial reaction time task reflect rodents' temporal strategies: evidence from no-light and pharmacological challenges. Psychopharmacology (Berl). 2016 10; 233(19-20):3513-25. PMID: 27534540.
      View in: PubMed
    8. Wallach J, Kang H, Colestock T, Morris H, Bortolotto ZA, Collingridge GL, Lodge D, Halberstadt A, Brandt SD, Adejare A. Pharmacological Investigations of the Dissociative 'Legal Highs' Diphenidine, Methoxphenidine and Analogues. PLoS One. 2016; 11(6):e0157021. PMID: 27314670; PMCID: PMC4912077.
    9. Brandt SD, Kavanagh PV, Westphal F, Elliott SP, Wallach J, Colestock T, Burrow TE, Chapman SJ, Stratford A, Nichols DE, Halberstadt A. Return of the lysergamides. Part II: Analytical and behavioural characterization of N6 -allyl-6-norlysergic acid diethylamide (AL-LAD) and (2'S,4'S)-lysergic acid 2,4-dimethylazetidide (LSZ). Drug Test Anal. 2017 Jan; 9(1):38-50. PMID: 27265891.
      View in: PubMed
    10. Halberstadt A, Hyun J, Ruderman MA, Powell SB. Effects of the psychotomimetic benzomorphan N-allylnormetazocine (SKF 10,047) on prepulse inhibition of startle in mice. Pharmacol Biochem Behav. 2016 09; 148:69-75. PMID: 27236030.
      View in: PubMed
    11. Brandt SD, Kavanagh PV, Dowling G, Talbot B, Westphal F, Meyer MR, Maurer HH, Halberstadt A. Analytical characterization of N,N-diallyltryptamine (DALT) and 16 ring-substituted derivatives. Drug Test Anal. 2017 Jan; 9(1):115-126. PMID: 27100373.
      View in: PubMed
    12. Manning EE, Halberstadt A, van den Buuse M. BDNF-Deficient Mice Show Reduced Psychosis-Related Behaviors Following Chronic Methamphetamine. Int J Neuropsychopharmacol. 2016 Apr; 19(4). PMID: 26453694; PMCID: PMC4851263.
    13. Halberstadt A, Sindhunata IS, Scheffers K, Flynn AD, Sharp RF, Geyer MA, Young JW. Effect of 5-HT2A and 5-HT2C receptors on temporal discrimination by mice. Neuropharmacology. 2016 08; 107:364-375. PMID: 27020041.
      View in: PubMed
    14. Halberstadt A. Behavioral and pharmacokinetic interactions between monoamine oxidase inhibitors and the hallucinogen 5-methoxy-N,N-dimethyltryptamine. Pharmacol Biochem Behav. 2016 Apr; 143:1-10. PMID: 26780349.
      View in: PubMed
    15. Halberstadt A, Slepak N, Hyun J, Buell MR, Powell SB. The novel ketamine analog methoxetamine produces dissociative-like behavioral effects in rodents. Psychopharmacology (Berl). 2016 Apr; 233(7):1215-25. PMID: 26758284.
      View in: PubMed
    16. Brandt SD, Kavanagh PV, Westphal F, Stratford A, Elliott SP, Hoang K, Wallach J, Halberstadt A. Return of the lysergamides. Part I: Analytical and behavioural characterization of 1-propionyl-d-lysergic acid diethylamide (1P-LSD). Drug Test Anal. 2016 Sep; 8(9):891-902. PMID: 26456305; PMCID: PMC4829483 [Available on 09/01/17].
    17. Nichols DE, Sassano MF, Halberstadt A, Klein LM, Brandt SD, Elliott SP, Fiedler WJ. N-Benzyl-5-methoxytryptamines as Potent Serotonin 5-HT2 Receptor Family Agonists and Comparison with a Series of Phenethylamine Analogues. ACS Chem Neurosci. 2015 Jul 15; 6(7):1165-75. PMID: 25547199; PMCID: PMC4505863.
    18. Halberstadt A. Recent advances in the neuropsychopharmacology of serotonergic hallucinogens. Behav Brain Res. 2015 Jan 15; 277:99-120. PMID: 25036425; PMCID: PMC4642895.
    19. Greer GR, Grob CS, Halberstadt A. PTSD symptom reports of patients evaluated for the New Mexico Medical Cannabis Program. J Psychoactive Drugs. 2014 Jan-Mar; 46(1):73-7. PMID: 24830188.
      View in: PubMed
    20. van Enkhuizen J, Geyer MA, Halberstadt A, Zhuang X, Young JW. Dopamine depletion attenuates some behavioral abnormalities in a hyperdopaminergic mouse model of bipolar disorder. J Affect Disord. 2014 Feb; 155:247-54. PMID: 24287168; PMCID: PMC3924859.
    21. Halberstadt A, Geyer MA. Effects of the hallucinogen 2,5-dimethoxy-4-iodophenethylamine (2C-I) and superpotent N-benzyl derivatives on the head twitch response. Neuropharmacology. 2014 Feb; 77:200-7. PMID: 24012658; PMCID: PMC3866097.
    22. Adams WK, Halberstadt A, van den Buuse M. Hippocampal serotonin depletion unmasks differences in the hyperlocomotor effects of phencyclidine and MK-801: quantitative versus qualitative analyses. Front Pharmacol. 2013; 4:109. PMID: 24009584; PMCID: PMC3756227.
    23. Halberstadt A, Geyer MA. Serotonergic hallucinogens as translational models relevant to schizophrenia. Int J Neuropsychopharmacol. 2013 Nov; 16(10):2165-80. PMID: 23942028; PMCID: PMC3928979.
    24. Toth M, Gresack JE, Hauger RL, Halberstadt A, Risbrough VB. The role of PKC signaling in CRF-induced modulation of startle. Psychopharmacology (Berl). 2013 Oct; 229(4):579-89. PMID: 23722830; PMCID: PMC3784645.
    25. Halberstadt A, Geyer MA. Characterization of the head-twitch response induced by hallucinogens in mice: detection of the behavior based on the dynamics of head movement. Psychopharmacology (Berl). 2013 Jun; 227(4):727-39. PMID: 23407781; PMCID: PMC3866102.
    26. Halberstadt A, Powell SB, Geyer MA. Role of the 5-HT2A receptor in the locomotor hyperactivity produced by phenylalkylamine hallucinogens in mice. Neuropharmacology. 2013 Jul; 70:218-27. PMID: 23376711; PMCID: PMC3934507.
    27. Amitai N, Weber M, Swerdlow NR, Sharp RF, Breier MR, Halberstadt A, Young JW. A novel visuospatial priming task for rats with relevance to Tourette syndrome and modulation of dopamine levels. Neurosci Biobehav Rev. 2013 Jul; 37(6):1139-49. PMID: 23010529; PMCID: PMC3556379.
    28. Tanaka S, Young JW, Halberstadt A, Masten VL, Geyer MA. Four factors underlying mouse behavior in an open field. Behav Brain Res. 2012 Jul 15; 233(1):55-61. PMID: 22569582; PMCID: PMC3866095.
    29. Halberstadt A, Buell MR, Price DL, Geyer MA. Differences in the locomotor-activating effects of indirect serotonin agonists in habituated and non-habituated rats. Pharmacol Biochem Behav. 2012 Jul; 102(1):88-94. PMID: 22487771; PMCID: PMC3354037.
    30. Halberstadt A, Nichols DE, Geyer MA. Behavioral effects of a,a,ß,ß-tetradeutero-5-MeO-DMT in rats: comparison with 5-MeO-DMT administered in combination with a monoamine oxidase inhibitor. Psychopharmacology (Berl). 2012 Jun; 221(4):709-18. PMID: 22222861; PMCID: PMC3796951.
    31. van den Buuse M, Ruimschotel E, Martin S, Risbrough VB, Halberstadt A. Enhanced effects of amphetamine but reduced effects of the hallucinogen, 5-MeO-DMT, on locomotor activity in 5-HT(1A) receptor knockout mice: implications for schizophrenia. Neuropharmacology. 2011 Jul-Aug; 61(1-2):209-16. PMID: 21501627; PMCID: PMC3866100.
    32. Halberstadt A, Geyer MA. Multiple receptors contribute to the behavioral effects of indoleamine hallucinogens. Neuropharmacology. 2011 Sep; 61(3):364-81. PMID: 21256140; PMCID: PMC3110631.
    33. Halberstadt A, Lehmann-Masten VD, Geyer MA, Powell SB. Interactive effects of mGlu5 and 5-HT2A receptors on locomotor activity in mice. Psychopharmacology (Berl). 2011 May; 215(1):81-92. PMID: 21153406; PMCID: PMC3072483.
    34. Halberstadt A, Koedood L, Powell SB, Geyer MA. Differential contributions of serotonin receptors to the behavioral effects of indoleamine hallucinogens in mice. J Psychopharmacol. 2011 Nov; 25(11):1548-61. PMID: 21148021; PMCID: PMC3531560.
    35. Grob CS, Danforth AL, Chopra GS, Hagerty M, McKay CR, Halberstadt A, Greer GR. Pilot study of psilocybin treatment for anxiety in patients with advanced-stage cancer. Arch Gen Psychiatry. 2011 Jan; 68(1):71-8. PMID: 20819978.
      View in: PubMed
    36. Halberstadt A, Nichols DE.(Muller CP, Jacobs B Eds.), Handbook of the Behavioral Neurobiology of Serotonin. Serotonin and serotonin receptors in hallucinogen action. 2010; 585-620.
    37. Quednow BB, Geyer MA, Halberstadt A. (Muller CP, Jacobs B Eds.), Handbook of the Behavioral Neurobiology of Serotonin. Serotonin and schizophrenia. 2010; 621-636.
    38. Halberstadt A, Geyer MA. LSD but not lisuride disrupts prepulse inhibition in rats by activating the 5-HT(2A) receptor. Psychopharmacology (Berl). 2010 Feb; 208(2):179-89. PMID: 19937319.
      View in: PubMed
    39. Halberstadt A, van der Heijden I, Ruderman MA, Risbrough VB, Gingrich JA, Geyer MA, Powell SB. 5-HT(2A) and 5-HT(2C) receptors exert opposing effects on locomotor activity in mice. Neuropsychopharmacology. 2009 Jul; 34(8):1958-67. PMID: 19322172; PMCID: PMC2697271.
    40. Halberstadt A, Geyer MA. Habituation and sensitization of acoustic startle: opposite influences of dopamine D1 and D2-family receptors. Neurobiol Learn Mem. 2009 Sep; 92(2):243-8. PMID: 18644244; PMCID: PMC2745310.
    41. Halberstadt A, Buell MR, Masten VL, Risbrough VB, Geyer MA. Modification of the effects of 5-methoxy-N,N-dimethyltryptamine on exploratory behavior in rats by monoamine oxidase inhibitors. Psychopharmacology (Berl). 2008 Nov; 201(1):55-66. PMID: 18604652; PMCID: PMC2929165.
    42. Cuccurazzu B, Halberstadt A. Projections from the vestibular nuclei and nucleus prepositus hypoglossi to dorsal raphe nucleus in rats. Neurosci Lett. 2008 Jul 04; 439(1):70-4. PMID: 18511198; PMCID: PMC2459230.
    43. Halberstadt A, Balaban CD. Selective anterograde tracing of nonserotonergic projections from dorsal raphe nucleus to the basal forebrain and extended amygdala. J Chem Neuroanat. 2008 Jul; 35(4):317-25. PMID: 18434087; PMCID: PMC2442033.
    44. Halberstadt A, Balaban CD. Selective anterograde tracing of the individual serotonergic and nonserotonergic components of the dorsal raphe nucleus projection to the vestibular nuclei. Neuroscience. 2007 Jun 15; 147(1):207-23. PMID: 17507165; PMCID: PMC2093990.
    45. Halberstadt A, Balaban CD. Anterograde tracing of projections from the dorsal raphe nucleus to the vestibular nuclei. Neuroscience. 2006 Dec 01; 143(2):641-54. PMID: 16989955.
      View in: PubMed
    46. Halberstadt A, Balaban CD. Serotonergic and nonserotonergic neurons in the dorsal raphe nucleus send collateralized projections to both the vestibular nuclei and the central amygdaloid nucleus. Neuroscience. 2006 Jul 07; 140(3):1067-77. PMID: 16600519.
      View in: PubMed
    47. Halberstadt A, Balaban CD. Organization of projections from the raphe nuclei to the vestibular nuclei in rats. Neuroscience. 2003; 120(2):573-94. PMID: 12890525.
      View in: PubMed
    48. Halberstadt A. The phencyclidine-glutamate model of schizophrenia. Clin Neuropharmacol. 1995 Jun; 18(3):237-49. PMID: 8635182.
      View in: PubMed